Overview

A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia

Status:
Withdrawn
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy. The pharmacokinetics, pharmacodynamics, and safety of the study drug will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
Enzon Pharmaceuticals, Inc.
Treatments:
Lectins